Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases

Abstract

<jats:sec><jats:title>Aims</jats:title><jats:p>Autoantibodies targeting Ro52 and Ro60 antigens are historically reported as anti SSA/Ro. In general anti SSA/Ro results are either anti Ro52+Ro60+ or anti Ro52−Ro60+ antibodies. Anti Ro52 without anti Ro60 (Ro52+ Ro60−) antibodies are often not reported routinely. This study intends to review the potential significance of these autoantibodies in the management of connective tissue diseases.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>A retrospective survey of Ro52+Ro60− was carried out as part of the service evaluation of extractable nuclear antigen antibodies (ENA) reporting from the immunology laboratory, the NHS Greater Glasgow and Clyde (GGC), UK. The clinical documents and laboratory results of 97 patients with Ro52+Ro60− and 100 patients with Ro52+Ro60+ were reviewed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Seventy-one patients (73%) with anti Ro52+Ro60− antibodies have been diagnosed with autoimmune conditions including undifferentiated connective tissue diseases (n=14, 14%), systemic lupus erythematosus (n=10, 10%), Sjögren’s syndrome (n=10, 10%) and rheumatoid arthritis (n=13, 13%). Twenty-three patients (24%) with anti Ro52+Ro60− antibodies have no autoimmune features but were found to have significant clinical conditions including malignancies. In contrast, 87 patients (87%) with anti Ro52+Ro60+ antibodies have autoimmune conditions including Sjögren’s syndrome (n=34, 34%), systemic lupus erythematosus (SLE; n=23, 23%), undifferentiated connective tissue diseases (n=12, 12%) and rheumatoid arthritis (n=6, 6%).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Anti Ro52 without anti Ro60 (Ro52+Ro60−) antibodies should be reported. In the majority of patients these autoantibodies were associated with various autoimmune diseases. Anti Ro52+Ro60− antibodies were also found in patients with significant clinical conditions including malignancies even though there was no suggestion of autoimmunity at the time of testing.</jats:p></jats:sec>

A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

“…Finally, our study is probably the first to report on MS the presence of anti-Ro52 abs, an autoab marker of prototype autoimmune rheumatic diseases such as systemic lupus erythematosus and Sjögren's syndrome. This autoab, which is relatively frequent and can be found in non-autoimmune rheumatic diseases, as monospecificity (anti-Ro52 ab positive in the absence of anti-Ro60/SSA ) [38][39][40][41][42] is only present in 2 (1.5%) MS patients, a prevalence unexpectedly low, given the reported high prevalence of ANA in MS, autoimmune nature of the disease, and the relatively high prevalence of anti-Ro52 abs in the general population; all three points raising the logical expectation of a higher percentage rate for this autoab specificity in MS. None of these two patients had concomitant anti-Ro60/SSA abs or clinical evidence of Sicca syndrome.…”

A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis

“…Finally, our study is probably the first to report on MS the presence of anti-Ro52 abs, an autoantibody marker of prototype autoimmune rheumatic diseases such as systemic lupus erythematosus and Sjögren's syndrome. This autoantibodies, which is relatively frequent and can be found in non-autoimmune rheumatic diseases, as monospecificity (anti-Ro52 antibody positive in the absence of anti-Ro60) [38][39][40][41][42] as only present in 2 (1.5%) MS patients, a prevalence unexpectedly low, given the reported high prevalence of ANA in MS, autoimmune nature of the disease, and the relatively high prevalence of anti-Ro52 abs in the general population; all three points raising the logical expectation of a higher percentage rate for this autoantibody's specificity in MS. None of these two patients had concomitant anti-Ro60 abs or clinical evidence of sicca syndrome.…”

Autoantibodies reactive to PEP08 are clinically related with morbidity and severity of interstitial lung disease in connective tissue diseases

“…Thus, analysis of the involvement of anti‐PL‐7 and anti‐Jo‐1 autoantibodies in ILD may contribute to understanding the morbidity and severity of many PEP08‐negative patients. It was recently reported that the production of Ro52‐autoAbs in patient sera were related to undifferentiated connective tissue diseases (UCTD) . Measurement of PEP08‐Ab in sera of UCTD patients may contribute to the prediction of ILD.…”